Application of Remimazolam Combined With Esketamine in Painless Gastroscopy and Colonoscopy in Elderly Patients

Launched by HARBIN MEDICAL UNIVERSITY · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new method of anesthesia for elderly patients undergoing painless procedures called gastroscopy and colonoscopy, which are tests used to examine the digestive system. The goal is to see if a combination of two medications, remimazolam and esketamine, can provide effective and safe anesthesia without using opioids, which are commonly used but can have more side effects. Researchers want to find out if this new approach is just as good or even better than the traditional method that includes opioids.

To participate in this trial, you need to be at least 65 years old and scheduled for one of these procedures. However, there are some health conditions that might prevent you from joining, such as serious liver or kidney problems, certain breathing disorders, or if you are taking specific medications. If you enroll, you can expect to receive either the new combination of medications or the standard opioid-based treatment during your procedure, and the medical team will closely monitor your health throughout. This study aims to ensure the safety and comfort of elderly patients during these important tests.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients undergoing painless gastroenteroscopy in outpatient clinics;
• • 2. aged 65 years and above;
• • 3. American Society of Anesthesiologists (ASA) grades I - III.
• Exclusion Criteria:
• • 1. Patients with abnormal liver or kidney function;
• • 2. known respiratory or endocrine diseases;
• • 3. Patients with uncontrolled hypertension and NYHA classification Ⅲ-Ⅳ;
• • 4. Taking monoamine oxidase inhibitors, sedatives, analgesics, hypnotics, antipsychotics, antiemetics or antidepressants;
• • 5. Addiction to tobacco and alcohol;
• • 6. Patients allergic to the investigational drug;
• • 7. expected difficult airway;
• • 8. Body mass index (BMI) \>35kg/m\^2;
• • 9. Have participated in other clinical trials within the past three months;
• • 10. Patients with psychosocial illness or cognitive dysfunction and inability to cooperate or communicate.